About Tenpoint Therapeutics
Tenpoint Therapeutics is a company based in Cambridge (United Kingdom) founded in 2020 by Jose Alain Sahel, Lyndon Da Cruz, Thomas Reh, Vanessa King, Pete Coffey, Olivier Goureau, and Deniz Dalkara. It operates as a HealthTech. Tenpoint Therapeutics has raised $155 million across 4 funding rounds from investors including Eight Roads Ventures, UCL Technology Fund and British Patient Capital. Tenpoint Therapeutics offers products and services including Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment. Tenpoint Therapeutics operates in a competitive market with competitors including Charles River Laboratories, Annexon, Cytel, Aldeyra and LabCorp, among others.
- Headquarter Cambridge, United Kingdom
- Founders Jose Alain Sahel, Lyndon Da Cruz, Thomas Reh, Vanessa King, Pete Coffey, Olivier Goureau, Deniz Dalkara
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tenpoint Therapeutics, Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$12.25 M (USD)-131as on Dec 31, 2022
-
EBITDA
-$13.27 M (USD)-136as on Dec 31, 2022
-
Total Equity Funding
$155 M (USD)
in 4 rounds
-
Latest Funding Round
$150 M (USD), Debt – Conventional
Jan 29, 2026
-
Investors
Eight Roads Ventures
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tenpoint Therapeutics
Tenpoint Therapeutics offers a comprehensive portfolio of products and services, including Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment.
Developed for treating presbyopia in aging eyes.
Formulated to address cataracts in aging patients.
Designed to treat geographic atrophy in eyes.
People of Tenpoint Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Tenpoint Therapeutics
Tenpoint Therapeutics has successfully raised a total of $155M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $150 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tenpoint Therapeutics
Tenpoint Therapeutics has secured backing from 11 investors, including venture fund investors. Prominent investors backing the company include Eight Roads Ventures, UCL Technology Fund and British Patient Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital co-investments are made in UK later-stage businesses.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked |
Investor details for Tenpoint Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tenpoint Therapeutics
Investment portfolio details for Tenpoint Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tenpoint Therapeutics
Detailed financials for Tenpoint Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tenpoint Therapeutics Comparisons
Peer comparison for Tenpoint Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tenpoint Therapeutics
Tenpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, Annexon, Cytel, Aldeyra and LabCorp, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of drug discovery and preclinical development services
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Provider of laboratory tests for physicians
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
Detailed competitors of Tenpoint Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tenpoint Therapeutics
Complete news archive for Tenpoint Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tenpoint Therapeutics
Tenpoint Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Tenpoint Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Eddy Anglade is the current CEO of Tenpoint Therapeutics.
Tenpoint Therapeutics is a funded company, having raised a total of $155M across 4 funding rounds to date.
Tenpoint Therapeutics is dedicated to pioneering treatments for rejuvenating vision in aging eyes. The company targets major ophthalmic indications such as presbyopia, cataracts, and geographic atrophy. Innovative solutions are being developed to address the largest unmet needs in eye care, with a pipeline aimed at transforming treatment paradigms. Operations span across multiple global locations to support research and development in the healthcare sector.
Tenpoint Therapeutics's top competitors include LabCorp, Annexon and Charles River Laboratories.
Tenpoint Therapeutics offers Brimochol PF, Cataract Treatment, and Geographic Atrophy Treatment.
Tenpoint Therapeutics has 11 investors. Key investors include Eight Roads Ventures, UCL Technology Fund, British Patient Capital, F-Prime Capital, and Sofinnova Partners.